AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02348268 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
Study NCT02348268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
Study NCT02348268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic therapy
Description: Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
Study NCT02348268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesic therapy
Description: Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
Study NCT02488538 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Daily record of severity of problems
Description: Women will record their symptoms daily using the daily record of severity of symptoms.
Study NCT01895101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 gr tranexamic acid
Description: This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
Study NCT01895101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
Study NCT02663518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0791800 (TTI-621)
Description: Monotherapy
Study NCT04168658 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Physical activity and education intervention
Description: At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~1. Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~2. Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~3. Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~4. Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months.
Study NCT04168658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education intervention
Description: Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
Study NCT00997958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days).
Study NCT05291793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenoxicam 20 Mg Powder for Solution for Injection Vial
Description: Tenoxicam 20 Mg Powder is mixed with dissolving solvent then administered intraarticularly
Study NCT05291793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 40 Mg (suspension) administered intraarticularly
Study NCT05291793 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 2ml sterile saline administered intraarticularly
Study NCT02931032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sampling of dental plaque / infected dentine
Description: A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
Study NCT01453140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Sirolimus
Description: On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily.
Study NCT01453140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2 with Cytoxan + Sirolimus
Description: Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide.
Study NCT01453140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
Description: Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off.
Study NCT01453140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and Sirolimus
Description: Day 1: Cyclophosphamide Day 2: Sirolimus
Study NCT01453140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2 with Cytoxan + Sirolimus
Description: treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus
Study NCT01453140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose IL-2, Vidaza, Cytoxan & Sirolimus
Description: Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
Study NCT03847766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRO-based follow-up
Description: Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
Study NCT03847766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRO-based telephone consultation
Description: diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
Study NCT02568761 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Injection Snoreplasty
Description: Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
Study NCT02568761 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal Exercises
Description: Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
Study NCT02884024 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: there is no intervention in this study
Study NCT00998465 — intervention group
Intervention type: OTHER
Intervention: 24-hour blood pressure
Description: Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
Study NCT00998465 — intervention group
Intervention type: OTHER
Intervention: Echocardiography
Description: Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
Study NCT00998465 — intervention group
Intervention type: OTHER
Intervention: Inert gas rebreathing
Description: Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
Study NCT00998465 — intervention group
Intervention type: RADIATION
Intervention: Dexa-scan
Description: Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
Study NCT00998465 — intervention group
Intervention type: RADIATION
Intervention: Plasma volume
Description: The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
Study NCT00998465 — intervention group
Intervention type: RADIATION
Intervention: Glomerular filtration rate (GFR)
Description: GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
Study NCT00998465 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
Study NCT00998465 — intervention group
Intervention type: OTHER
Intervention: Urine analyses
Description: 24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
Study NCT00998465 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Diets with low and high sodium content
Description: Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
Study NCT00269308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic Manual treatment + home exercise ( procedure+behavior)
Description: The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active
Study NCT00269308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise + home exercise
Description: The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active
Study NCT00269308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
Study NCT04301466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qi Zhi Tong Luo capsule
Description: Patients were receiveed Qi Zhi Tong Luo Capsule 4 capsules, 2 times per day for 24 weeks. QZTL capsule, a traditional Chinese medicine. Each capsule was weighted 0.5g.
Study NCT04301466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients were allocated to placebo, 4 capsules, 2 times per day for 24 weeks.To preserve blinding, the placebo had an identical taste and appearance to the experimental drugs. Placebo (batch number: 20140805) were produced by Shanxi Zhendong Pharmaceutical Co., Ltd.
Study NCT00743249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI MONOKA canalicular stent, 10 mm
Description: 40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
Study NCT00743249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINI MONOKA canalicular stent, 20 mm
Description: 40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
Study NCT03936608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming individualized RV-LV pacing offset to optimize ECG
Description: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
Study NCT02663518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07901800 (TTI-621) plus Rituximab
Description: Combination therapy
Study NCT02663518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07901800 (TTI-621) plus Nivolumab
Description: Combination therapy
Study NCT03936608 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nominally programming CRT device without RV-LV offset
Description: After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
Study NCT04546490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure Release technique
Description: Manual therapy technique used by the treatment of Myofsacial Trigger points. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point and increasing the pressure as he perceives a reduction in the resistance offered by the soft tissue under the finger
Study NCT04546490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischemic pressure technique
Description: Manual therapy technique by making pressure in Myofascial Trigger Point. The therapist will apply it with the first and second finger on the previously marked Myofascial Trigger Point. This is performed until the patient's tolerance, when he refers a decrease in pain or have a correct adaptation to the perceived pain increase the pressure to a new painful barrier.
Study NCT01272232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study NCT00353522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 24 weeks
Study NCT00353522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: 900mg po daily for 24 weeks
Study NCT01940224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Preoperative administration of pregabalin 300mg
Study NCT01940224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Preoperative administration of placebo
Study NCT01940224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: Postoperative administration of morphine via PCA pump for 48h
Study NCT01272232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study NCT01272232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
Study NCT01940224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Postoperative administration of morphine via PCA pump for 48h
Study NCT02856477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine analysis
Description: a sample of urine is collected during 8 hours.
Study NCT05379478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment of antibody profiles
Description: Antibody profiles will be determined on submitted plasma samples
Study NCT02632435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PICC
Description: Participants will be randomized to a PICC for vascular access during chemotherapy.
Study NCT02632435 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PORT
Description: Participants will be randomized to a PORT for vascular access during chemotherapy
Study NCT05555966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Activation Mapping Guided Cardiac resynchronization therapy
Description: To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
Study NCT03850366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: GVHD prophylaxis
Study NCT01935635 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPDCs-T immune therapy
Description: HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2\*105-1\*106 cells per time,total 12 times;
Study NCT01052103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: 40 milligrams (mg), oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20 mg or a maximum of 80 mg.
Study NCT01052103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
Study NCT01052103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
Study NCT01052103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: United States (U.S.) label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
Study NCT02143752 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness
Description: Group behavioral intervention using mindfulness to help smokers quit smoking
Study NCT02143752 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quit Line
Description: see arm
Study NCT00626132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Eucommia
Description: two capsules three times a day orally for 2 weeks
Study NCT00626132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eucommia
Description: two capsules three times a day orally for 2 weeks
Study NCT00978523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
Description: Oral, dose-escalation
Study NCT00434213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daytrana
Description: Methylphenidate Transdermal System (MTS)
Study NCT01854853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STYLE Brazil
Description: Multifamily group HIV/STI Prevention Intervention
Study NCT01854853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: Health promotion intervention
Study NCT01990729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: ARTRA
Description: ARTRA (glucosamine and chondroitin sulfate)
Study NCT03386825 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Antineoplastic agents, protein kinase inhibitor (L01XE21)
Study NCT01123876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
Study NCT01181323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
Study NCT01181323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted live attenuated influenza virus vaccine, trivalent
Description: Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
Study NCT01181323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
Study NCT01181323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
Study NCT03724773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-Arm Cast
Description: A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.